**Name of Journal: *World Journal of Clinical Cases***

**ESPS Manuscript NO: 19264**

**Manuscript Type:** **CASE REPORT**

**Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir**

Suga T *et al*. Adverse events during interferon-free therapy

**Takayoshi Suga, Ken Sato, Yuichi Yamazaki,Tatsuya Ohyama, Norio Horiguchi, Satoru Kakizaki, Motoyasu Kusano, Masanobu Yamada**

**Takayoshi Suga, Ken Sato, Yuichi Yamazaki,Tatsuya Ohyama, Norio Horiguchi, Satoru Kakizaki, Masanobu Yamada,** Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan

**Motoyasu Kusano,** Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital, Maebashi, Gunma 371-8511, Japan

**Author contributions**: Suga T collected, analyzed and interpreted the data; Sato K drafted the article and analyzed and interpreted the data; Yamazaki Y, Ohyama T, Horiguchi N, Kakizaki S and Kusano M analyzed the data; Yamada M approved the final version of the manuscript.

**Institutional review board statement:** Institutional review board in our institute does not require more than obtaining written informed consent regarding “Case report”.

**Informed consent statement:** We obtained written informed consent.

**Conflict-of-interest statement**:The authors have declared no conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Ken Sato, MD, PhD,** Department of Medicine and Molecular Science,Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. [satoken@gunma-u.ac.jp](mailto:satoken@gunma-u.ac.jp)

**Telephone:** +81-272-208127

**Fax:** +81-272-208137

**Received:** May 1, 2015

**Peer-review started:** May 8, 2015

**First decision:** July 17, 2015

**Revised:** September 25, 2015

**Accepted:** October 20, 2015

**Article in press:**

**Published online:**

**Abstract**

A 66-year-old, interferon-ineligible, treatment-naive man who was diagnosed with chronic hepatitis C due to hepatitis C virus genotype 1b began combination therapy with daclatasvir and asunaprevir. On day 14 of treatment, hepatic reserve and renal function deterioration was observed, while his transaminase levels were normal. Both daclatasvir and asunaprevir were discontinued on day 18 of treatment, because the patient complained of dark urine and a rash on his trunk and four limbs. After discontinuing antiviral therapy, the abnormal laboratory finding and clinical manifestations gradually improved, without recurrence. Our case fulfilled the diagnostic criteria of probable drug reaction with eosinophilia and systemic symptom (DRESS) syndrome. Despite the 18-day treatment, sustained virological response 12 was achieved. Based on the clinical course, we concluded that there was a clear cause-and-effect relationship between the treatment and adverse events. To our knowledge, this patient represents the first case of probable DRESS syndrome that includes concomitant deterioration of hepatic reserve and renal function due to combination therapy with daclatasvir and asunaprevir, regardless of normalization of transaminase levels. Our case suggests that we should pay attention not only to the transaminase levels but also to allergic symptoms associated with organ involvement during combination therapy with daclatasvir and asunaprevir.

**Key words**: Hepatitis C; Daclatasvir; Asunaprevir; Hepatic reserve deterioration; Renal dysfunction

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Oral combination therapy with daclatasvir and asunaprevir for chronic hepatitis C demonstrates a relatively favorable safety profile. Although the incidence of hyperbilirubinemia, hypoalbuminemia, and a decreased prothrombin activity have been reported, as well as renal damage, concomitant deterioration of hepatic reserve and renal function without transaminase elevations have not been reported. We observed probable drug reaction with eosinophilia and systemic symptom syndrome, including concomitant deterioration of hepatic reserve and renal function due to the combination therapy, regardless of normalized transaminase levels. Thus, our case highlights the importance of paying attention not only to transaminase levels but also to the allergic symptoms associated with organ involvement during combination therapy.

Suga T, Sato K, Yamazaki Y, Ohyama T, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. *World J Clin Cases* 2015; In press

**INTRODUCTION**

Combination therapy with daclatasvir and asunaprevir has been approved as oral antiviral therapy for chronic hepatitis C due to hepatitis C virus (HCV) genotype 1b. This new type of therapy resulted in a sustained virological response (SVR) rate of over 80% after 24 wk of therapyfor chronic hepatitis C patients with genotype 1b[1,2]. In Japan, combination therapy with daclatasvir and asunaprevir has been recommended for interferon-ineligible patients based on the Japan Society of Hepatology (JSH) guidelines for managing HCV infection[3].

One of the most frequent adverse events during combination therapy with daclatasvir and asunaprevir is elevated alanine aminotransferase (ALT) levels. In an open-label trial of oral antiviral therapy conducted in Japan[1,4,5], ALT elevations occurred in 17.6% of the patients treated with a combination of asunaprevir and daclatasvir. The incidence of hyperbilirubinemia, hypoalbuminemia or prothrombin activity decrease, which reflect deteriorated hepatic reserve[6-8], were 3.9%, 1.2% or 0.8%, respectively[1,4,5]. The incidence of renal damage was 0.4%[1,4,5]. However, concomitant deterioration of hepatic reserve and renal function without transaminase elevations has not been reported. Here, we report a case of chronic hepatitis C with concomitant deterioration of hepatic reserve and renal function that fulfilled the diagnostic criteria of probable drug reaction with eosinophilia and systemic symptom (DRESS) syndrome[9] due to combination therapy with daclatasvir and asunaprevir. We got written informed consent from the patient in advance.

**CASE REPORT**

A 66-year-old man, diagnosed with chronic hepatitis C (genotype 1b) at the age of 50, was started on a scheduled 24-week course of daclatasvir and asunaprevir for elevated transaminase levels. The patient suffered from a duodenal ulcer, bronchial asthma, hypertension and cerebral hemorrhage. He had undergone antihypertensive therapy with nifedipine and olmesartan for 5 years. These drugs were maintained throughout the antiviral treatment. No relevant family history was noted. The patient did not have a past history or predisposing factors for liver disease, except for chronic hepatitis C. He had no history of drug allergies, although he did have bronchial asthma. Combination therapy with daclatasvir (60 mg once daily) and asunaprevir (100 mg twice daily) was selected because the patient was both interferon-ineligible and interferon-naïve due to his past history of hypertension and cerebral hemorrhage. A V170I mutation in the NS3 lesion was detected by direct sequencing prior to the therapy. Before beginning therapy, the following measurements were noted: serum alanine aminotransferase (ALT), 57 IU/L; total bilirubin, 0.5 mg/dL; albumin, 4.1 g/dL; creatinine, 0.7 mg/dL; prothrombin activity, 102%; total white cell count, 5000/μL (eosinophils 150/μL); platelet count, 11.1 ×104/μL; C-reactive protein, < 0.1 mg/dL, and HCV RNA, 5.9 Log IU/mL.

On day 14 of treatment, the patient’s laboratory findings showed concomitant deterioration of hepatic reserve and renal function, without any subjective symptoms. Although the ALT level had decreased to 22 IU/mL, serum total bilirubin had worsened to 1.9 mg/dL, albumin to 3.3 g/dL, creatinine to 1.4 mg/dL, prothrombin activity to 66.4 %, total white cell count to 12130/μL (eosinophils 121 /μL), platelet count to 7.9 × 104/μL and C-reactive protein to 3.5 mg/dL (Table 1). Abdominal ultrasonography revealed splenomegaly, which was not present before the therapy. There was no evidence of biliary obstruction. Asunaprevir and daclatasvir were continued. The patient complained of headache, dark urine and a partly fused erythematous rash on his trunk and four limbs on day 18 of treatment. In view of the skin lesions, a dermatologist diagnosed the skin rash as a drug eruption or untypical urticarial lesion (Figure 1), although the patient’s vital signs were normal: temperature 36.5 ℃, blood pressure 121/58 mmHg and heart rate 72/min. Both daclatasvir and asunaprevir were discontinued based on the dermatologist’s advice and the patient’s request, and an antihistamine was administered for 2 wk. When observed on day 21 of the initiation of treatment, the clinical manifestations had disappeared, and the laboratory findings had returned to normal ranges, except for the serum albumin (3.4 g/dL), prothrombin activity (74.5%) and eosinophilia (2673/μL) levels. These measurements also returned to normal ranges, until day 35 of the initiation of treatment. On day 42 of the initiation of treatment, molecular biological analysis detected Epstein-Barr virus (EBV) DNA but not human herpesvirus (HHV)-6 and HHV-7 DNA in the serum. Although daclatasvir and asunaprevir were discontinued on day 18 of treatment, SVR 12 was achieved (serum HCV RNA was negative at 12 wk of treatment). The clinical course of our case and the time course for the critical laboratory values are shown in Figure 2 and Table 2, respectively.

**DISCUSSION**

Here, we described a case of deteriorated hepatic reserve and renal function during combination therapy with daclatasvir and asunaprevir, regardless of normalized transaminase levels at the development of the symptoms. The decreased cholinesterase and total cholesterol values were also consistent with deteriorated hepatic reserve[10,11]. Drug-induced liver injury generally results in abnormal biochemical liver tests, including transaminase or alkaline phosphatase[12]. In our case, the normal values of transaminase and alkaline phosphatase did not fulfill the diagnostic criteria of drug-induced liver injury. However, the clinical course was similar to that of drug-induced liver injury, key elements of which are drug exposure preceding the onset of liver injury, the exclusion of underlying liver disease, including obstructive jaundice, and improvement after discontinuing the drug[12,13]. Because there have been case reports showing severe liver injury or hepatic decompensation during the therapy of direct-acting antivirals, including telaprevir[14] or simeprevir[15], daclatasvir or asunaprevir may also induce liver injury, with deteriorated hepatic reserve.

The present case also demonstrated renal damage and rash on the trunk and four limbs, which were accompanied by inflammatory reaction and eosinophilia after starting therapy, thereby indicating the possibility of drug-induced hypersensitivity syndrome (DIHS). The patient’s atopic background, including bronchial asthma, was also a risk factor of drug allergy[16]. In fact, a case associated with DIHS during combination therapy with daclatasvir and asunaprevir has been reported[17]. The renal damage was not due to dehydration or urinary tract infection; thus, organ involvement associated with a series of symptoms was considered. Rapidly enlarging rash and deteriorating hepatic reserve, as well as eosinophilia and EBV reactivation[18], are the typical hallmark features of DIHS, which might be responsible for the pathophysiology in our case. However, the lack of fever, lymphadenopathy, and human herpesvirus (HHV)-6 reactivation were inconsistent with DIHS. Thus, our case did not fulfil the diagnostic criteria of even atypical DIHS, according to the diagnostic criteria of DIHS[19]. During this therapy, our case was fundamentally different from the case associated with DIHS[17] because our patient did not have lymphadenopathy, fever, ALT elevation or other organ involvement, such as renal damage.

However, as a severe, adverse, drug-induced reaction, DRESS syndrome is similar to DIHS. DRESS syndrome is characterized by a delayed onset, usually 2-6 wk after the initiation of drug therapy, as well as the possible persistence or aggravation of symptoms, despite the discontinuation of the causative drug; severe skin eruption, fever, hematologic abnormalities (eosinophilia or atypical lymphocytes) and internal organ involvement are also associated with DRESS syndrome. In this case, the patient showed eosinophilia (more than 1500/μL, with a DRESS score of 2), and skin rash (more than 50%), which were indicative of DRESS; in addition, there was liver and kidney involvement and the absence of other potential causes (each with a DRESS score of 1). There were no enlarged lymph nodes or atypical lymphocytes, and the skin biopsy was not performed, thus each received a DRESS score of 0, and high fever was not observed (less than 38.5 ℃, with a DRESS score of -1). However, the resolution within 15 d is uncertain. If we estimate this evaluation item at a score of -1, the score of our case was at least 5; therefore, our case was considered to be a probable case, according to the RegiSCAR scoring system[9]. The possible mechanisms of the DRESS syndrome are detoxification defects, which can lead to reactive metabolite formation and subsequent immunological reactions, slow acetylation, and reactivation of human herpesvirus, including EBV, HHV-6 and -7[9].

Both daclatasvir and asunaprevir are metabolized by CYP3A, and asunaprevir is a substrate of OATP1B1[20]. CYP3A activity and OATP1B1 activity are known to be decreased in advanced liver disease and cirrhosis[21,22]. Prior to antiviral therapy, the platelet count, hyaluronic acid and type IV collagen levels suggested hepatic fibrosis in our case[23,24]. Moreover, nifedipine (one of the concomitant drugs) is metabolized by CYP3A and, thus, may compete against daclatasvir and asunaprevir as the substrate. Another concomitant drug, olmesartan, is a substrate of OATP1B1 and, thus, may compete against daclatasvir and asunaprevir as the substrate. Drug interactions may also increase the blood concentration of daclatasvir and asunaprevir. Therefore, higher blood levels of daclatasvir or asunaprevir (based on low hepatic metabolic ability) might cause unexpected adverse events. Indeed, in our case, the achievement of SVR12 supported this hypothesis. As a combination therapy, daclatasvir and asunaprevir are also approved in compensated cirrhosis patients (Child-Pugh A), and careful observation is particularly needed for these patients.

Based on the decreased prothrombin activity and platelet count, disseminated intravascular coagulopathy (DIC) was a differential diagnosis in our case. Unfortunately, we did not measure the fibrin degradation products (FDP), D-dimer, and fibrinogen levels at the onset of the deteriorated laboratory data. According to the ISTH Diagnostic Scoring System for DIC, the score in our case was considered to be 5, at most. Thus, we think that overt DIC was a possible but not the probable diagnosis.

In summary, we experienced an unusual case of probable DRESS syndrome due to combination therapy with daclatasvir and asunaprevir. We should pay attention not only to the transaminase levels but also to the allergic symptoms associated with organ involvement during combination therapy with daclatasvir and asunaprevir.

**COMMENTS**

***Case characteristics***

Dark urine and a rash on his trunk and four limbs.

***Clinical diagnosis***

DRESS syndrome due to combination therapy with daclatasvir and asunaprevir.

***Differential diagnosis***

The ISTH Diagnostic Scoring System for DIC and diagnostic criteria of DIHS.

***Laboratory diagnosis***

Blood drawing and urine collection showed that hepatic reserve and renal function deterioration, eosinophilia and dark urine, respectively.

***Imaging diagnosis***

Inspection of skin and photographic evidence of a skin rash.

***Pathological diagnosis***

Not applicable.

***Treatment***

Both daclatasvir and asunaprevir were discontinued and an antihistamine was administered for 2 wk.

***Related reports***

The reference #1 for the understanding of combination therapy with daclatasvir and asunaprevir, and #9 for the understanding of The DRESS syndrome.

***Term explanation***

DRESS syndrome: DRESS syndrome is characterized by a delayed onset, usually 2-6 w after the initiation of drug therapy, as well as the possible persistence or aggravation of symptoms, despite the discontinuation of the causative drug; severe skin eruption, fever, hematologic abnormalities (eosinophilia or atypical lymphocytes) and internal organ involvement are also associated with DRESS syndrome.

***Experiences and lessons***

We should pay attention not only to the transaminase levels but also to the allergic symptoms associated with organ involvement during combination therapy with daclatasvir and asunaprevir.

***Peer-review***

It is a very interesting and well explained case worth sharing with the scientific community.

**REFERENCES**

1 **Kumada H**, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. *Hepatology* 2014; **59**: 2083-2091 [PMID: 24604476 DOI: 10.1002/hep.27113]

2 **Manns M**, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. *Lancet* 2014; **384**: 1597-1605 [PMID: 25078304 DOI: 10.1016/s0140-6736(14)61059-x]

3 **Drafting Committee for Hepatitis Management Guidelines,** the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2014 Update for Genotype 1. *Hepatol Res* 2014; **44** Suppl S1: 59-70 [PMID: 24397840 DOI: 10.1111/hepr.12272]

4 **Suzuki Y**, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, McPhee F, Hughes E, Kumada H. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. *J Hepatol* 2013; **58**: 655-662 [PMID: 23183526 DOI: 10.1016/j.jhep.2012.09.037]

5 **Chayama K**, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. *Hepatology* 2012; **55**: 742-748 [PMID: 21987462 DOI: 10.1002/hep.24724]

6 **Sherlock SP**. Biochemical investigations in liver disease; some correlations with hepatic histology. *J Pathol Bacteriol* 1946; **58**: 523-544 [PMID: 20283090]

7 **Rothschild MA**, Oratz M, Zimmon D, Schreiber SS, Weiner I, Van Caneghem A. Albumin synthesis in cirrhotic subjects with ascites studied with carbonate-14C. *J Clin Invest* 1969; **48**: 344-350 [PMID: 5765785 DOI: 10.1172/jci105990]

8 **Robert A**, Chazouillères O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? *Hepatology* 1996; **24**: 1392-1394 [PMID: 8938167 DOI: 10.1053/jhep.1996.v24.pm0008938167]

9 **Cacoub P**, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC. The DRESS syndrome: a literature review. *Am J Med* 2011; **124**: 588-597 [PMID: 21592453 DOI: 10.1016/j.amjmed.2011.01.017.]

10 **Burnett W**. An assessment of the value of serum cholinesterase as a liver function test and in the diagnosis of jaundice. *Gut* 1960; **1**: 294-302 [PMID: 13689170]

11 **Habib A**, Mihas AA, Abou-Assi SG, Williams LM, Gavis E, Pandak WM, Heuman DM. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. *Clin Gastroenterol Hepatol* 2005; **3**: 286-291 [PMID: 15765449]

12 **Fontana RJ**, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, Hoofnagle JH. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. *Hepatology* 2010; **52**: 730-742 [PMID: 20564754 DOI: 10.1002/hep.23696]

13 **Navarro VJ**, Senior JR. Drug-related hepatotoxicity. *N Engl J Med* 2006; **354**: 731-739 [PMID: 16481640 DOI: 10.1056/NEJMra052270]

14 **Gordon SC**, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, Maliakkal B, Alam I, Stewart TG, Vainorius M, Peter J, Nelson DR, Fried MW, Reddy KR. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. *J Hepatol* 2015; **62**: 286-293 [PMID: 25218788 DOI: 10.1016/j.jhep.2014.08.052]

15 **Stine JG**, Intagliata N, Shah NL, Argo CK, Caldwell SH, Lewis JH, Northup PG. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. *Dig Dis Sci* 2015; **60**: 1031-1035 [PMID: 25373453 DOI: 10.1007/s10620-014-3422-x]

16 **Idsoe O**, Guthe T, Willcox RR, de Weck AL. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. *Bull World Health Organ* 1968; **38**: 159-188 [PMID: 5302296]

17 **Fujii Y**, Uchida Y, Mochida S. Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir. *Hepatology* 2015; **61**: 400-401 [PMID: 25308083 DOI: 10.1002/hep.27559]

18 **Seishima M**, Yamanaka S, Fujisawa T, Tohyama M, Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. *Br J Dermatol* 2006; **155**: 344-349 [PMID: 16882173 DOI: 10.1111/j.1365-2133.2006.07332.x]

19 **Shiohara T**, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. *Br J Dermatol* 2007; **156**: 1083-1084 [PMID: 17381452]

20 **Kiser JJ**, Burton JR, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 596-606 [PMID: 23817323 DOI: 10.1038/nrgastro.2013.106]

21 **Chalasani N**, Gorski JC, Patel NH, Hall SD, Galinsky RE. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. *Hepatology* 2001; **34**: 1103-1108 [PMID: 11731998 DOI: 10.1053/jhep.2001.29306]

22 **Kojima H**, Nies AT, König J, Hagmann W, Spring H, Uemura M, Fukui H, Keppler D. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. *J Hepatol* 2003; **39**: 693-702 [PMID: 14568249]

23 **Fontana RJ**, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. *Hepatology* 2008; **47**: 789-798 [PMID: 18175357 DOI: 10.1002/hep.22099]


24 **George DK**, Ramm GA, Walker NI, Powell LW, Crawford DH. Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis. *J Hepatol* 1999; **31**: 47-52 [PMID: 10424282]

**P-Reviewer:** Palmero D, Reviriego C **S-Editor:** Tian YL

**L-Editor: E-Editor:**



**Figure 1** **Skin rash on the patient’s trunk on day 14 of the treatment with daclatasvir and asunaprevir.**



**Figure 2** **Clinical course of a patient with concomitant deterioration of hepatic reserve and renal function due to combination treatment with daclatasvir and asunaprevir.**

**Table 1 Laboratory findings before antiviral therapy and at the onset of adverse events**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **On day 14 of antiviral therapy** | | | | **Virological analysis before antiviral therapy** | |
| Hematology |  | Virus markers |  | Virus marker |  |
| WBC (ìL) | 12130 | IgM-HAV Ab | ( - ) | HCV RNA ( Log IU/mL) | 5.9 |
| Neutrophils (%) | 82 | HBs Ag | ( - ) |  |  |
| Lymphocytes (%) | 10 | IgM-HBc Ab | ( - ) | Drug resistant variants |  |
| Monocytes (%) | 6 | HBV DNA | ( - ) | NS3/V36A | ( - ) |
| Eosinophils (%) | 1 | IgA-HEV Ab | ( - ) | NS3/T54A | ( - ) |
| RBC (ìL) | 4000000 | IgM-HSV Ab | ( - ) | NS3/T54S | ( - ) |
| Hb (g/dL) | 13.2 | IgG-HSV Ab | (＋) | NS3/Q80L | ( - ) |
| Plt (ìL) | 79000 | IgM-HHV6 Ab | ( - ) | NS3/Q80R | ( - ) |
|  |  | IgG-HHV6 Ab | (＋) | NS3/R155K | ( - ) |
| Blood Chemistry |  | IgM-CMV Ab | ( - ) | NS3/R155Q | ( - ) |
| TP (g/dL) | 7.4 | IgG-CMV Ab | (＋) | NS3/R155T | ( - ) |
| Albumin (g/dL) | 3.3 | IgM-EBV VCA Ab | ( - ) | NS3/A156S | ( - ) |
| T-Bil (mg/dL) | 1.9 | IgG-EBV VCA Ab | (＋) | NS3/A156T | ( - ) |
| D-Bil (mg/dL) | 0.7 | EBNA Ab | (＋) | NS3/A156V | ( - ) |
| AST (IU/L) | 15 |  |  | NS3/D168A | ( - ) |
| ALT (IU/L) | 22 | Endocrine |  | NS3/D168E | ( ± )2 |
| ALP (IU/L) | 284 | TSH (ìIU/mL) | 1.7 | NS3/D168H | ( - ) |
| ã-GTP (IU/L) | 33 | fT3 (pg/mL) | 2.81 | NS3/D168T | ( - ) |
| LDH (IU/L) | 147 | fT4 (ng/dL) | 1.1 | NS3/D168V | ( - ) |
| ChE (IU/L) | 257 |  |  | NS3/V170I | (+)2 |
| T. Chol (mg/dL) | 126 | Serology |  | NS5A/L31F | ( - ) |
| BUN (mg/dL) | 28 | IgA (mg/dL) | 130 | NS5A/L31M | ( - ) |
| Cr (mg/dL) | 1.4 | IgE (mg/dL) | 526 | NS5A/L31V | ( - ) |
| UA (mg/dL) | 5.4 | IgG (mg/dL) | 2225 | NS5A/Y93H | ( ± ) 2 |
| CPK (IU/L) | 60 | IgM (mg/dL) | 104 |  |  |
| CRP (mg/dL) | 3.5 | RF | ( - ) |  |  |
| BNP (pg/mL) | 20.1 | ANA | ×40 (＋) |  |  |
| Fe (ìg/dL) | 123 | AMA | ( - ) |  |  |
| Ferritin (ng/mL) | 115 | ASMA | ( - ) |  |  |
| Hyaluronic Acid1 (ng/mL) | 179 |  |  |  |  |
| Collagen-41 (ng/mL) | 298 | Tumor markers |  |  |  |
|  |  | PIVKA-2 (mAU/mL) | 19 |  |  |
| Blood coagulation |  | AFP (ng/mL) | 6.6 |  |  |
| PT (%) | 66.4 |  |  |  |  |
| PT-INR | 1.22 | DLST |  |  |  |
|  |  | Daclatasvir | ( - ) |  |  |
|  |  | Asunaprevir | ( - ) |  |  |

1Hyaluronic acid and collagen-4 were measured before antiviral therapy. Drug resistant variants in the NS3 and NS5A regions were measured by invader method; 2D168E and Y93H mutaions were not ditected by direct sequencing. Only V170I was detected by direct sequencing. ã-GTP: ã-glutamyl transpeptidase; Ab: Antibody; AFP: á-fetoprotein; Ag: Antigen; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AMA: Antimitochondrial antibody; ANA: Antinuclear antibody; ASMA: Antismooth muscle antibody; AST: Aspartate aminotransferase; BNP: Brain natriuretic polypeptide; BUN: Blood urea nitrogen; ChE: Cholinesterase; CMV: Cytomegalovirus; CPK: Creatine phospho kinase; CRP: C-reactive protein; D-Bil: Direct bilirubin; DLST: Drug-induced lymphocyte stimulation test; EBNA: Epstein–Barr virus nuclear antigen; EBV: Epstein-Barr virus; fT3: Free triiodothyronine; fT4: Free thyroxine; HAV: Hepatitis A virus; Hb: Hemoglobin; HBc: Hepatitis B virus core; HBs: Hepatitis B virus surface; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HEV: Hepatitis E virus; HHV: Human herpes virus; HSV: Herpes simplex virus; Ig: Immunoglobulin; INR: International normalized ratio; LDH: Lactic dehydrogenase; PIVKA: Protein induced by vitamin K absence or antagonist; Plt: Platelets; PT: Prothrombin time; RBC: Red blood cells; RF: Rheumatoid factor; T-Bil: Total bilirubin; T.Chol: Total cholesterol; TP: Total protein; TSH: Thyroid stimulating hormone; UA: Uric acid; WBC: White blood cells.

**Table 2 Time course of critical laboratory values**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Before antiviral therapy** | **Day 14 of treatment** | **Day 21 of the initiation of treatment (Day 3 after discontinuation of the treatment)** | **Day 35 of the initiation of treatment (Day 17 after discontinuation of the treatment)** |
| Hematology |  |  |  |  |
| WBC (ìL) | 5000 | 12130 | 7800 | 5950 |
| Neutrophils (%) |  | 82 | 35 | 47 |
| Lymphocytes (%) |  | 10 | 26 | 43 |
| Monocytes (%) |  | 6 | 6 | 7 |
| Eosinophils (%) |  | 1 | 32 | 3 |
| Plt (ìL) | 111000 | 79000 | 130000 | 115000 |
|  |  |  |  |  |
| Blood Chemistry |  |  |  |  |
| Albumin (g/dL) | 4.1 | 3.3 | 3.4 | 4.2 |
| T-Bil (mg/dL) | 0.5 | 1.9 | 0.4 | 0.5 |
| D-Bil (mg/dL) | 0 | 0.7 | 0.1 | 0.1 |
| AST (IU/L) | 57 | 15 | 17 | 28 |
| ALT (IU/L) | 57 | 22 | 18 | 23 |
| ChE (IU/L) | 311 | 257 | 204 | 276 |
| T. Chol (mg/dL) | 170 | 126 | 140 | 179 |
| BUN (mg/dL) | 13 | 28 | 6 | 16 |
| Cre (mg/dL) | 0.7 | 1.4 | 0.6 | 0.8 |
| CRP (mg/dL) | 0.1 | 3.5 | 0.6 | 0 |
|  |  |  |  |  |
| Blood coagulation |  |  |  |  |
| PT (%) | 102 | 66.4 | 74.5 | 95.5 |
| PT-INR | 1.01 | 1.22 | 1.16 | 1.04 |

WBC: White blood cells; Plt: Platelets; PT: Prothrombin time; T-Bil: Total bilirubin; T. Chol: Total cholesterol; TP: Total protein; CRP: C-reactive protein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ChE: Cholinesterase.